NeuroMetrix, Inc.: directors' dealings · United States · SEC (Form 4)

About NeuroMetrix, Inc.

NeuroMetrix, Inc. is a U.S.-based medical technology company that was historically listed on the NASDAQ market in the United States under the ticker NURO. The company was founded in June 1996 by Shai N. Gozani, M.D., Ph.D., and is headquartered in Woburn, Massachusetts. NeuroMetrix built its reputation as a commercial-stage neurotechnology business focused on unmet needs in chronic pain and neurological disorders, combining product development, manufacturing, regulatory affairs, commercialization, and customer support within a relatively compact operating footprint. The company’s core legacy products were Quell® and DPNCheck®. Quell® is a wearable neuromodulation platform designed to help treat fibromyalgia symptoms and lower-extremity chronic pain through a non-pharmacological, at-home approach. DPNCheck® is a point-of-care screening test used to assess peripheral neuropathy, particularly in diabetes-related settings. Together, these products placed NeuroMetrix at the intersection of chronic pain management, peripheral nerve assessment, and decentralized diagnostics. The company has described itself as having helped create the market for point-of-care nerve testing while also introducing sophisticated wearable technology for chronic pain therapy. From a competitive standpoint, NeuroMetrix operated as a niche innovator rather than a scaled diversified medtech platform. Its value proposition depended on proprietary intellectual property, clinical differentiation, regulatory positioning, and the ability to secure physician adoption and reimbursement. That makes its business model more specialized than that of larger medtech peers, but also potentially more exposed to adoption and commercialization risks. Geographically, the company was primarily centered in the United States, with corporate and production facilities in Woburn, Massachusetts, while its devices had also been commercialized in select international markets over time. The most important recent development is the company’s corporate transaction in 2025. In December 2024, NeuroMetrix announced a definitive merger agreement with electroCore, and the deal closed on May 1, 2025. SEC filings indicate that NURO was subsequently delisted from NASDAQ and became an indirect wholly owned subsidiary of electroCore. The transaction also excluded the DPNCheck business, which was divested before closing. For investors, this is a key context point: NeuroMetrix should now be viewed less as an independent public equity story and more as a legacy U.S. medtech asset that has been folded into a larger bioelectronic health-and-wellness platform.